Literature DB >> 8594693

Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria.

M B van Hensbroek1, S Morris-Jones, S Meisner, S Jaffar, L Bayo, R Dackour, C Phillips, B M Greenwood.   

Abstract

Whether children with malarial anaemia should receive supplementation with iron or folic acid is uncertain. Therefore, the effects of supplementary treatment with iron or folic acid, given together with chloroquine or pyrimethamine-sulfadoxine (Fansidar), has been assessed in 600 Gambian children with uncomplicated falciparum malaria. After one month, haematological recovery was significantly better in the group treated with Fansidar than in the chloroquine-treated group (difference in mean haemoglobin level = 0.54 g/dL, P = 0.01). Children who received iron had a significantly better response than those given placebo (differences in mean haemoglobin level after one month and at dry season follow-up = 0.70 g/dL, P = 0.006, and 0.81 g/dL, P = 0.001, respectively). Iron supplementation was not associated with increased prevalence of malaria. Supplementation with folic acid did not improve the haematological response but, among children who received Fansidar, the treatment failure rate was significantly higher among those given folic acid than among those given placebo. Thus, supplementation with iron, but not folic acid, improves haematological recovery without increasing susceptibility to malaria.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8594693     DOI: 10.1016/0035-9203(95)90438-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  29 in total

Review 1.  Integrated management of childhood infections and malnutrition: a global initiative.

Authors:  H Campbell; S Gove
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

Review 2.  The role of folate in malaria - implications for home fortification programmes among children aged 6-59 months.

Authors:  Roland Kupka
Journal:  Matern Child Nutr       Date:  2015-12       Impact factor: 3.092

Review 3.  Oral iron supplements for children in malaria-endemic areas.

Authors:  Ami Neuberger; Joseph Okebe; Dafna Yahav; Mical Paul
Journal:  Cochrane Database Syst Rev       Date:  2016-02-27

Review 4.  The role of antioxidants treatment on the pathogenesis of malarial infections: a review.

Authors:  Murtala Bindawa Isah; Mohammed Auwal Ibrahim
Journal:  Parasitol Res       Date:  2014-02-13       Impact factor: 2.289

5.  Severe anemia in Malawian children.

Authors:  Job Cj Calis; Kamija S Phiri; E Brian Faragher; Bernard J Brabin; Imelda Bates; Luis E Cuevas; Rob J de Haan; Ajib I Phiri; Pelani Malange; Mirriam Khoka; Paul Jm Hulshof; Lisette van Lieshout; Marcel Ghm Beld; Yik Y Teo; Kirk A Rockett; Anna Richardson; Dominic P Kwiatkowski; Malcolm E Molyneux; Michaël Boele van Hensbroek
Journal:  Malawi Med J       Date:  2016-09       Impact factor: 0.875

Review 6.  Iron metabolism and the innate immune response to infection.

Authors:  Erin E Johnson; Marianne Wessling-Resnick
Journal:  Microbes Infect       Date:  2011-10-20       Impact factor: 2.700

Review 7.  Effect of iron supplementation on incidence of infectious illness in children: systematic review.

Authors:  Tarun Gera; H P S Sachdev
Journal:  BMJ       Date:  2002-11-16

8.  Relation between vitamin B12 and folate status, and hemoglobin concentration and parasitemia during acute malaria infections in Colombia.

Authors:  Olga Caicedo; Eduardo Villamor; Yibby Forero; José Ziade; Pilar Pérez; Francisco Quiñones; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Acta Trop       Date:  2009-12-02       Impact factor: 3.112

Review 9.  Iron metabolism in children: confounding factors.

Authors:  Gary M Brittenham
Journal:  Food Nutr Bull       Date:  2007-12       Impact factor: 2.069

Review 10.  The contribution of clinical pharmacology to antimalarial drug discovery and development.

Authors:  Peter Winstanley
Journal:  Br J Clin Pharmacol       Date:  2003-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.